Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review

ABSTRACT Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a rare inborn immune error characterized by a triad of chronic mucocutaneous candidiasis (CMC), hypoparathyroidism (HP), and adrenal insufficiency (ADI). Methods: Literature search was conducted in PubMed, Web of Science, and Scopus databases using related keywords, and included studies were systematically evaluated. Results: We reviewed 938 APECED patients and the classic triad of APECED was detected in 57.3% (460 of 803) of patients. CMC (82.5%) was reported as the earliest, HP (84.2%) as the most prevalent, and ADI (72.2%) as the latest presentation within the classic triad. A broad spectrum of non-triad involvements has also been reported; mainly included ectodermal dystrophy (64.5%), infections (58.7%), gastrointestinal disorders (52.0%), gonadal failure (42.0%), neurologic involvements (36.4%), and ocular manifestations (34.3%). A significant positive correlation was detected between certain tissue-specific autoantibodies and particular manifestations including ADI and HP. Neutralizing autoantibodies were detected in at least 60.0% of patients. Nonsense and/or frameshift insertion-deletion mutations were detected in 73.8% of patients with CMC, 70.9% of patients with HP, and 74.6% of patients with primary ADI. Conclusion: Besides penetrance diversity, our review revealed a diverse affected ethnicity (mainly from Italy followed by Finland and Ireland). APECED can initially present in adolescence as 5.2% of the patients were older than 18 years at the disease onset. According to the variety of clinical conditions, which in the majority of patients appear gradually over time, clinical management deserves a separate analysis.

[1]  V. Strand,et al.  Type I interferon, anti-interferon antibodies, and COVID-19 , 2021, The Lancet Rheumatology.

[2]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[3]  M. Nireekshan Kumar,et al.  Autoimmune polyendocrine syndrome type 1 (APECED) in the Indian population: case report and review of a series of 45 patients , 2020, Journal of Endocrinological Investigation.

[4]  I. Abdullahi,et al.  Biological and clinical significance of T helper 17 cell deficiency: insight into monogenic defects. , 2020, European annals of allergy and clinical immunology.

[5]  A. Aghamohammadi,et al.  Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review , 2020, Frontiers in Immunology.

[6]  Wesley P. Wong,et al.  Dual functions of Aire CARD multimerization in the transcriptional regulation of T cell tolerance , 2020, Nature Communications.

[7]  J. Casanova,et al.  Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification , 2020, Journal of Clinical Immunology.

[8]  J. Casanova,et al.  Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee , 2020, Journal of Clinical Immunology.

[9]  D. Mollura,et al.  Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance , 2019, Science Translational Medicine.

[10]  G. Constantine,et al.  Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy , 2018, Immunological reviews.

[11]  J. Wemeau,et al.  Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1 , 2018, Front. Immunol..

[12]  N. Kutukculer,et al.  Familial inheritance and screening of first-degree relatives in common variable immunodeficiency and immunoglobulin A deficiency patients , 2018, International journal of immunopathology and pharmacology.

[13]  Mark S. Anderson,et al.  Dominant-negative loss of function arises from a second, more frequent variant within the SAND domain of autoimmune regulator (AIRE). , 2017, Journal of autoimmunity.

[14]  M. Gershwin,et al.  The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). , 2017, Autoimmunity reviews.

[15]  P. Knappskog,et al.  Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1 , 2017, The Journal of clinical endocrinology and metabolism.

[16]  E. Husebye,et al.  AIRE-mutations and autoimmune disease. , 2016, Current opinion in immunology.

[17]  E. Cirillo,et al.  Novel Findings into AIRE Genetics and Functioning: Clinical Implications , 2016, Front. Pediatr..

[18]  H. Kong,et al.  Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. , 2016, JCI insight.

[19]  Mark S. Anderson,et al.  AIRE expands: new roles in immune tolerance and beyond , 2016, Nature Reviews Immunology.

[20]  J. B. Oliveira,et al.  Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. , 2015, The Journal of clinical investigation.

[21]  Mark S. Anderson,et al.  Transglutaminase 4 as a prostate autoantigen in male subfertility , 2015, Science Translational Medicine.

[22]  W. Newman,et al.  Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. , 2015, Immunity.

[23]  M. Puig-Domingo,et al.  New Splice Site Acceptor Mutation in AIRE Gene in Autoimmune Polyendocrine Syndrome Type 1 , 2014, PloS one.

[24]  P. Peterson,et al.  Anti-Cytokine Autoantibodies Preceding Onset of Autoimmune Polyendocrine Syndrome Type I Features in Early Childhood , 2013, Journal of Clinical Immunology.

[25]  Javier Martín,et al.  Association of the AIRE gene with susceptibility to rheumatoid arthritis in a European population: a case control study , 2013, Arthritis Research & Therapy.

[26]  Q. Xing,et al.  A Functional Alternative Splicing Mutation in AIRE Gene Causes Autoimmune Polyendocrine Syndrome Type 1 , 2013, PloS one.

[27]  A. Meloni,et al.  Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients. , 2012, The Journal of clinical endocrinology and metabolism.

[28]  Yusuke Nakamura,et al.  The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. , 2011, Human molecular genetics.

[29]  Mark S. Anderson,et al.  Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect. , 2010, The New England journal of medicine.

[30]  A. Fischer,et al.  Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I , 2010, The Journal of experimental medicine.

[31]  J. Perheentupa,et al.  Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I , 2009, Journal of internal medicine.

[32]  C. Janson,et al.  Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen , 2009, Proceedings of the National Academy of Sciences.

[33]  Pärt Peterson,et al.  Transcriptional regulation by AIRE: molecular mechanisms of central tolerance , 2008, Nature Reviews Immunology.

[34]  A. Gennery,et al.  Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. , 2008, The Journal of clinical endocrinology and metabolism.

[35]  L. Peltonen,et al.  Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. , 2008, The New England journal of medicine.

[36]  T. Hökfelt,et al.  Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1 , 2007, Proceedings of the National Academy of Sciences.

[37]  R. Tazi-Ahnini,et al.  Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. , 2002, Tissue antigens.

[38]  F. Mantero,et al.  Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. , 2002, Endocrine reviews.

[39]  C. Marcocci,et al.  A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  S. Antonarakis,et al.  A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients , 1998, Human Genetics.

[41]  J. Haavik,et al.  Identification of tryptophan hydroxylase as an intestinal autoantigen , 1998, The Lancet.

[42]  J. Zlotogora,et al.  Polyglandular autoimmune syndrome type I among Iranian Jews. , 1992, Journal of medical genetics.

[43]  J. Perheentupa,et al.  Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. , 1990, The New England journal of medicine.

[44]  A. Miettinen,et al.  Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. , 1987, The Journal of clinical endocrinology and metabolism.

[45]  B. Oftedal,et al.  Aire Mutations and Autoimmune Diseases , 2019, Thymus Transcriptome and Cell Biology.

[46]  C. Betterle,et al.  Clinical review 93: Autoimmune polyglandular syndrome type 1. , 1998, The Journal of clinical endocrinology and metabolism.

[47]  L. Peltonen,et al.  An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21 , 1994, Nature Genetics.